Inhibrx Biosciences, Inc. operates as a clinical-stage biopharmaceutical company specializing in the discovery and development of next-generation protein therapeutics. The company's proprietary modular protein engineering platforms enable the creation of multivalent biologics with optimized binding characteristics and pharmacokinetic properties. Its clinical pipeline is primarily focused on oncology, featuring lead candidates such as ozekibart (INBRX-109), a tetravalent death receptor 5 (DR5) agonist for solid tumors like chondrosarcoma, and INBRX-106, a hexavalent OX40 agonist. Headquartered in La Jolla, California, the company became an independent, publicly traded entity in May 2024. This occurred after Sanofi acquired its former parent company and spun out the remaining clinical and preclinical assets into this new corporate structure.
